TWiV 1150: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin dives into West Nile virus in New Jersey, poliovirus vaccination campaign in Gaza and Afghanistan, California dengue virus infections, children dying from flu, mpox vaccination procurement and antiviral usage, flu circulation in US, before reviewing the recent statistics on SARS-CoV-2 infection, finding a new wasterwater dashboard, if the monovalent XBB.1.5 COVID-19 vaccine is effective against circulating SARS-CoV-2 isolates, the need for nasal mucosal IgA in response to SARS-CoV-2 infection, where to find PEMGARDA, does administration of molnupiravir reduce symptoms in the vaccinated, when to use convalescent plasma, how molnupiravir treatment leads to better outcomes 3 and 6 months after treatment, a reminder of how and when to use steroids to treat COVID-19, what do when healthcare workers succumb to SARS-CoV-2 infection, if vaccination against SARS-CoV-2 does protect against long COVID, and if those taking the anti-diabetic drug metformin have higher or lower incidences of long COVID.

Become a patron of TWiV!

• West Nile virus in New Jersey (CBSNews)
• Poliovirus vaccination 90% coverate (Reuters)
• Suspension of poliovirus eradication by the Taliban (apnews)
• California dengue cluster (CIDRAP)
• Children dying of influenza (CIDRAP)
• 199 children deaths from flu (CDC)
• Bavarian Nordic mpox vaccine (Yahoo finances)
• Prequalification of MVA-BN mpox vaccine (WHO Int)
• Speed doses of mpox vaccine (CIDRAP)
• GAVI rapidly secures 500K doses of mpox vaccines for Africa(GAVI)
• Expanded access to teconvirimat for mpox treatment in US 2022-2023(NEJM Evidence)
• FluView (CDC)
• Human to human transmission of bird flu in Missouri? (NY Times)
• Bird flu isolated from humans in Missouri similar to that found in cattle (CNN)
• COVID-19 deaths (CDC)
• COVID-19 national and regional trends (CDC)
• Waste water scan for 11 pathogens (WastewaterSCan)
• COVID-19 variant tracker (CDC)
• SARS-CoV-2 genomes galore (Nextstrain)
• Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage (CID)
• Early, robust mucosal secretory IgA but not IgG response to SARS-CoV-2 spike in oral fluid is associated with faster viral clearance and COVID-19 symptom resolution (JID)
• Suggestion for the use of a new preventive COVID-19 agent (IDSA)
• IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)
• Where to get pemgarda (Pemgarda)
• EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Drug interaction checker (University of Lierpool)
• Molnupiravir outcomes 3 and 6 months after treatment (LANCET Infectious Diseases)
• Antivirals and post-COVID-19 conditions (LANCET Infectious Disease)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What to do when sick with a respiratory virus (CDC)
• When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids, dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Metformin use in adults with diabetes and incidence of long COVID (Diabetes Care)
• Letters read on TWiV 1150
• Dr. Griffin's COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv